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Abstract
Partial gain of chromosome arm 17q is an abundant aberrancy in various cancer types such as lung and prostate cancer with
a prominent occurrence and prognostic significance in neuroblastoma – one of the most common embryonic tumors. The
specific genetic element/s in 17q responsible for the cancer-promoting effect of these aberrancies is yet to be defined
although many genes located in 17q have been proposed to play a role in malignancy. We report here the characterization
of a naturally-occurring, non-reciprocal translocation der(X)t(X;17) in human lung embryonal-derived cells following
continuous culturing. This aberrancy was strongly correlated with an increased proliferative capacity and with an acquired
ability to form colonies in vitro. The breakpoint region was mapped by fluorescence in situ hybridization (FISH) to the
17q24.3 locus. Further characterization by a custom-made comparative genome hybridization array (CGH) localized the
breakpoint within the Bromodomain PHD finger Transcription Factor gene (BPTF), a gene involved in transcriptional
regulation and chromatin remodeling. Interestingly, this translocation led to elevation in the mRNA levels of the
endogenous BPTF. Knock-down of BPTF restricted proliferation suggesting a role for BPTF in promoting cellular growth.
Furthermore, the BPTF chromosomal region was found to be amplified in various human tumors, especially in
neuroblastomas and lung cancers in which 55% and 27% of the samples showed gain of 17q24.3, respectively. Additionally,
42% percent of the cancer cell lines comprising the NCI-60 had an abnormal BPTF locus copy number. We suggest that
deregulation of BPTF resulting from the translocation may confer the cells with the observed cancer-promoting phenotype
and that our cellular model can serve to establish causality between 17q aberrations and carcinogenesis.
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Introduction
Structural alterations in chromosomes (commonly termed
aneuploidy or chromosomal aberrations) have been repeatedly
reported to associate with malignancy. Although not in all cases a
causal relationship has been proven, it is clear that abnormal
rearrangements of chromosomes during mitosis can lead to
carcinogenic events by deregulating proliferation-controlling
pathways. Genetic alterations could pave the path leading to
malignancy by several ways: in the most straight forward manner
loss of a tumor suppressor gene (by deletion) or gain of an
oncogene (by amplification) could unleash a proliferative pathway.
A prominent example is amplification of the N-myc proto-
oncogene, the copy number of N-myc is substantially elevated in
some human tumors and far exceeds the normal two-copy state
[1,2]. In that case a proliferative phenotype will prevail by the
sheer number of N-myc proteins produced as a result of the high
copy number. Another possibility is miscoding of a fusion protein
that render it unregulated and thus pro-cancerous. An event such
as this is the hallmark of chronic myeloid leukemia - the BCR-ABL
fusion (also termed the Philadelphia chromosome). The resulting
fusion of ABL with BCR deregulates the normally well-controlled
ABL protein, causing it to emit strong growth-promoting signals
[3]. A third option is deregulation of a cancer-related gene by
locating it near regulatory regions of another gene. Again, the myc
proto-oncogene can serve as an example. Structural aberrations in
the c-myc region on chr8q24 separate the c-myc gene from its
normal promoter and place it under the control of one of three
highly active promoters. Each of these promoters regulate an
immunoglobin gene. Once expression is controlled by the
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are highly active will express large quantities of c-myc which will
drive the relentless proliferation of cells, eventually leading to
lymphomas [4].
In addition to well-defined molecular models reasoning the
advantage potentially gained by certain aberrations, numerous
regions in the genome are targets for aberrations that are
associated with cancer but are yet to be rationalized molecularly.
One such region is 17q. aberrations in 17q are linked to several
cancer types such as lung [5,6,7], breast [8], prostate [9,10], liver
[11] and gastric cancer [10]. Structural alterations in 17q are most
prominent in neuroblastoma cases and are linked to aggressive
tumors [12,13].
Using various methods, we have characterized a novel
translocation occurring at the 17q24.3 locus within the BPTF
gene in lung embryonic cells that strongly correlates with a pre-
malignant phenotype. BPTF knock-down experiments restrict cell
proliferation and thus suggest that aberrant expression of BPTF
due to the translocation may contribute to malignancy. Lastly, we
present clinical data in which the BPTF locus is amplified in
human tumors and cancer cell lines proposing a role for aberrant
BPTF expression in human cancer.
Results
Partial trisomy of 17q is correlated to a pre-malignant
phenotype in lung embryonic cells
Giving the strong correlation between chromosomal rearrange-
ments and malignancy we examined the genomic integrity of cells
derived from a normal, non-cancerous human tissue undergoing
prolonged culturing. Three pools of WI-38 cells (lung embryonic
fibroblasts cells) were separately immortalized by ectopic over-
expression of the catalytic subunit of telomerase – hTERT,
providing the cells with unlimited growth potential [14]. We were
interested in monitoring the genomic structure of these cells with
time without any further intervention that may facilitate any pro-
cancerous advantage. Basically, only the first step in the long path
leading to transformation was artificially introduced to the cells
and then the cells were allowed to proliferate uninterrupted. The
proliferation rate of the cells was fixed for 150 population
doublings (PDLs) which stretched for roughly 250 days. At this
stage a change in the rate of proliferation was observed. While one
cell population (termed WI-38T) retained a fixed proliferation
rate, the two other populations started to proliferate in an
accelerated manner. These two cell populations were termed WI-
38T
HP-1/2 (for ‘Highly-Proliferating –1 and 2’) (Figure 1A).
Furthermore, WI-38T
HP-1/2 cells, in contrast to WI-38T, were
able to form colonies in vitro (Figure 1B). Therefore, WI-38T
HP-1/2
cells spontaneously obtained several pre-malignant traits –
excessive proliferation, colony-formation ability and loss of contact
inhibition. Of note, WI-38T
HP-2 cells were more proficient in
those traits than WI-38T
HP-1 and thus constitute a more aggressive
population.
Changes in chromosomal arrangement are considered as one of
the triggers for pre-malignant phenotypes such as that presented
by WI-38T
HP-1/2. In order to examine the possibility that such
rearrangements occurred in WI-38T
HP-1/2 we performed a
spectral karyotyping (SKY) analysis on parental WI-38, WI-38T
and WI-38T
HP-1/2. WI-38 and WI-38T cells exhibited a normal
diploid karyotype (except for some abnormalities that were not
consistent across the metaphases examined). In contrast, a non-
reciprocal translocation der(X)t(X;17) was observed in 9 out of 10
of the examined metaphases of WI-38T
HP-1/2 (Figure 2A and
[14]). Fluorescence in situ hybridization (FISH) analysis of WI-
38T
HP-1 confirmed gain of 17q25 in the distal end of chromosome
Xq (Figure 2B, on Figure 2C an illustration of the translocation is
depicted). Taken together, these findings show a correlation
between a pre-malignant phenotype of WI-38T
HP-1/2 cells and the
partial 17q trisomy that characterize these cells.
The translocation breakpoint is mapped to the BPTF
gene within the 17q24.3 region
In order to more specifically localize the chromosomal break-
point we performed FISH analysis using consecutive tandem
bacterial artificial chromosome (BAC) probes, starting with a
probe detecting the sub-telomeric region of 17q, followed by a
probe detecting a region less distant from the centromere and so
on (Figure 3A). A total of 11 probes (starting with the sub-
telomeric probe to probe RP11-387O17) were detected both on
the full chromosome 17 and on Xqter of WI-38T
HP-1 cells,
suggesting a partial trisomy of these genomic areas, evidenced by
probes on chromosome X. In contrast, the probes designed to
identify regions 17q24.3 and 17q24.1 were only detected on the
full chromosome 17 (probes RP11-304I14 and RP11-51F6
respectively). This probe-signal pattern mapped the breakpoint
to the 17q24.3 region enclosed between probes RP11-387O17 and
Figure 1. Highly proliferating WI-38T (WI-38T
HP-1/2) exhibit pre-malignant phenotypes. (A) The growth curve of WI-38T and WI-38T
HP-1/2
cells over 10 days is depicted. (B) The colony formation capability of WI-38T and WI-38T
HP-1/2 is depicted.
doi:10.1371/journal.pone.0009657.g001
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stretches for an area of about 0.5Mbp. Six coding sequences reside
within this area: BPTF, LOC284018, SH3GLP3, LOC440461,
SLC16A6 and KIAA1001. No rearrangements of Xq fragments
were detected as the two most distal probes detecting Xqter,
RP11-402H and RP11-26A4, revealed normal ploidy (Figure 3C).
After confining the area of the breakpoint to a specific
chromosomal region we set out to characterize the exact location
of this breakpoint. To this end, we performed a comparative
genomic hybridization assay (CGH). We have designed a custom
CGH array in which focus was put on the breakpoint region. This
0.5Mbp-long region in 17q was subjected to a large number of
probes giving an average distance of 500 bp between two probes.
Chromosome Xq was also scanned with a high-resolution probe
design. As shown in Figure 4A the CGH output showed a clear-cut
1.5 fold increase in probe intensity in the 17q region starting from
the fourth intron of the BPTF gene, stretching on to the sub-
telomeric end of 17q. This 1.5 fold increase in the signal suggests a
gainofthedetected chromosomalregion(i.e.partialtrisomyof17q).
In agreement with the FISH analysis, the CGH output represented
normal ploidy of Xq (data not shown). Therefore, we have
succeeded in mapping the breakpoint region to a 4 Kb-long region
within the fourth intron of BPTF (chr17: 63,307,829 - 63,311,794).
This region is densely packed with 12 repetitive elements (7 SINEs
and 5 LINEs – Figure 5). As repetitive elements are known to be
fragile and therefore considered hot spots for breakpoints it is
conceivable that these elements contributed to this rearrangement
event.Further indicationofthe breakpoint location wasachievedby
quantitative real time PCR (QRT-PCR) performed with primers
annealingto genomic regions of the BPTF gene. The level of a PCR
productofanamplified59genomicregionofBPTF wascomparable
in WI-38T and WI-38T
HP-1/2. In contrast, when amplifying a 39
genomic region of BPTF a ,1.5 fold increase in the level of the
PCR product was observed in WI-38T
HP-1/2 relative to its level in
WI-38T (Figure 4B).
Knock-down of excessive BPTF negates the pre-
malignant phenotype of WI-38T
HP-1/2
Next, we were interested in assessing BPTF mRNA level. We
used two primer sets in a QRT-PCR analysis, one set detected the
Figure 2. The WI-38T
HP-1/2 cells harbor the der(X)t(X;17) translocation. (A) Spectral karyotyping (SKY) analysis of WI-38T and WI-38T
HP-1/2
(passage 94) reveals a non-reciprocal translocation. The der(X)t(X;17) translocation is circled. (B) Fluorescence in situ hybridization (FISH) of 17q25
region in metaphase of WI-38T
HP-1 cells. The probe detecting the sub-telomeric region of 17q25 (red) is visible on two copies of chr17 and on one
copy of chrX. The chrX centromeric region is marked in green. (C) An illustration of the der(X)t(X;17) translocation.
doi:10.1371/journal.pone.0009657.g002
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9657Figure 3. Mapping of the der(X)t(X;17) breakpoint. (A) A scheme of the bacterial artificial chromosome (BAC) probes used for the FISH analysis
in order to localize the translocation. Filled squares represent probes detecting 17q material on both 17q and Xq, empty squares represent probes
detecting 17q material only on 17q and not on Xq. A magnification of the breakpoint region is illustrated on the left-hand side of the panel. (B) The
breakpoint region is localized in the 17q24.3 region. Fluorescence in situ hybridization analysis along the 17q arm of WI-38T
HP-1 reveals the
breakpoint region in the interval between two probes: RP11-387O17 (left-hand side – red) which is detected on chrX in addition to its normal position
on chr17. In contrast, probe RP11-304I14 (right-hand side – red) is detected only on the two normal copies of chr17 and not on chrX. ChrX material is
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second set detected the last exon of BPTF, an area duplicated as a
result of the translocation. The results were intriguing as both the
non-duplicated region and the duplicated region were elevated
(Figure 6). The fact that the non-duplicated region is also up-
regulated transcriptionaly suggests that the translocation affects the
regulation of the endogenous BPTF transcript and not only the
rearranged area. In addition, the mRNA level of BPTF in WI-
38T
HP-2 was highest whereas WI-38T
HP-1 exhibited an interme-
diate level of BPTF mRNA. This finding complements the data
shown in Figure1A and B where WI-38T
HP-2 presented the most
aggressive phenotype and a milder phenotype was presented in
WI-38T
HP-1. Therefore, a correlation exists between BPTF
mRNA level and an aggressive phenotype.
In order to elucidate the effect of the BPTF translocation WI-
38T and WI-38T
HP-1/2 cells were transfected with small-
interfering oligonucleotides targeting BPTF (si-BPTF) (si-BPTF-1
targeted the translocated region while si-BPTF-2 targeted the
endogenous region of BPTF) causing a reduction in BPTF mRNA
level (Figure 6B). Interestingly, when the translocated region of
BPTF was knocked-down (si-BPTF-1), BPTF level was equally
reduced in all three populations, however, when the non-
translocated region of BPTF was knocked-down (si-BPTF-2)
BPTF was reduced, but the expression pattern of BPTF resembled
that of the control (in which WI-38T
HP-2 exhibit the highest levels
of BPTF followed by WI-38T
HP-1 and then WI-38T). When the
growth capacity of WI-38T and WI-38T
HP-1/2 was assessed using
crystal violet staining an attenuated growth rate was observed in
cells treated with either of the two types of si-BPTF (Figure 6C and
6D). A similar pattern of growth attenuation was observed using a
cell counter (data not shown). Importantly, a strong correlation
between BPTF levels and the growth inhibition effect was noticed
as the most pronounce effect in growth inhibition was witnessed in
WI-38
HP-2 while an intermediate effect in WI-38T
HP-1 and a mild
effect in WI-38T were witnessed, indicating that BPTF is one of
the major players that contribute to the pre-malignant phenotypes
observed. Taken together, these data support a notion that
translocation-dependent dysregulation of BPTF is responsible for
the pre-malignant phenotype of WI-38T
HP-1/2.
The significance of the translocation was further highlighted
when WI-38T
HP-1 cells were introduced with GSE56 (a dominant
negative peptide targeting the p53 tumor suppressor) and a
constitutively active Ras oncoprotein (H-Ras
V12) which resulted in
many chromosomal aberrations as visualized by SKY (Figure 7A).
This aggressive sub-population of WI-38T
HP-1 resulted in full-
grown tumors when 10
7 cells were subcutaneously injected to five
nude mice [15]. The only translocation present in all five tumors
examined as visualized by SKY was the original der(X)t(X;17)
translocation (Figure 7B) while none of the other rearrangements
present in the cells prior to injection were detected. The fact that
this translocation, after constant selection pressure subjected in vivo,
was the only chromosomal aberrancy inhabiting the tumor cells
alludes to its advantageous tumorigenic properties to the cells.
Furthermore, the same experimental setup was repeated but with
a different p53-inactivating method. In Figure 7C a FISH analysis
of a mouse-originated tumor is shown in which p53 was
inactivated by short-hairpin RNA targeting p53 (sh-p53). Here,
the probe detecting the translocation (RP11-387O17) showed that
the rearrangement event existed in the tumor.
Gain of the BPTF locus is a frequent aberrancy in
neuroblastomas, lung adenocarcinomas and in various
cancer cell lines
In order to evaluate the gene dosage of BPTF in human tumors,
commercially available tumor arrays containing 143 tumor
samples from six human cancer types (neuroblastomas, lung
adenocarcinomas, nephroblastomas, leukemias, colon cancer and
retinoblastomas) were assessed. FISH analysis using probe RP11-
387O17 (detecting 17q24.3 region in the BPTF locus) and a probe
detecting chr17 centromeric material to distinguish between
polysomy and gain of the BPTF locus was performed. Several
genomic aberrations were observed in the BPTF locus in the
various tumor types such as polysomy, partial trisomy of 17q24.3
and gain of 17q24.3 (Figure 8A). This analysis revealed that 55%
of neuroblastomas and 27% of lung tumors exhibited gain of
17q24.3, followed by leukemia and colon cancer in which 20%
and 14% of the tumors examined presented gain of 17q24.3,
respectively. No such abnormalities were detected in retinoblas-
tomas and nephroblastomas (Figure 8B). Importantly, in 67% of
the BPTF-positive lung tumors cases, gain of the 17q24.3 locus
was associated with poor prognosis (grade III), while only 37% of
the cases were graded either II or I. Regarding the other tumor
types, grading was either not available (neuroblastomas, nephro-
blastomas, leukemias, retinoblastomas) or was not significant due
to small sample size. In accordance with that, an in silico analysis
using the ONCOMINE database [16] revealed significant
elevation in BPTF mRNA levels in several human cancers (lung,
brain, ovary and salivary gland) (Figure 8C).
To further investigate the copy number status of the BPTF locus
in different cancer types, we analyzed the BPTF locus status in the
60 cell lines composing the NCI-60 panel [17]. We inspected
several genomic locations inside the BPTF locus using the NCI-60
CGH dataset described in [18]. For all these genomic locations we
observed that 25 of the 60 cell lines contained an amplified BPTF
locus (42%) while only 2 had deletions in this locus. We also note
that amplifications of the 17qter are in general prevalent in the
NCI-60 cell lines.
The fact that gain of the BPTF locus and up-regulation of the
BPTF gene epitomize many human cancers indicates that our
cellular model with a defined 17q24.3 translocation located within
BPTF causing an elevation in endogenous BPTF could shed light
on cancer-associated 17q translocations and that BPTF could be
an important player in development of those malignancies.
Discussion
In this work we have shown that the 17q24.3 region is
translocated in human lung embryonic fibroblasts and that this
event perfectly correlated to a high proliferation rate. The
translocation breakpoint was mapped to the BPTF gene suggesting
a role for BPTF in proliferation. These data was strengthened by
BPTF knock-down experiments showing inhibition of prolifera-
tion. Unfortunately, attempts made at cloning and over-expressing
the BPTF gene were unfruitful due to its gigantic mRNA
(,11 Kb). In addition, it was impossible to asses the translocated
BPTF protein levels since the available antibodies against BPTF
did not produce a band in several western blot analyses that we
performed (Orbigen, cat# PAB-02251 and Bethyl cat# A300-
marked in green. (C) No aberrations in chromosome Xq material are detected. Fluorescence in situ hybridization along Xq arm. The two probes
detecting the most distant area of the Xq arm (RP11-304H and RP11-26A - red) are visible only on the two copies of chrX and not on chr17. The chr17
centromeric region is marked in green.
doi:10.1371/journal.pone.0009657.g003
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9657Figure 4. Localization of the breakpoint region within the fourth intron of BPTF gene. (A) DNAsamples from primary WI-38andWI-38T
HP-1
were labeled and hybridized to Agilent custom arrays covering the 0.5-Mb region (the distance between probe RP11-387O17 and RP11-304I14) on
chromosome 17 with an average probe spacing of 0.5 kb. (B) Quantitative Real-Time PCR analysis on genomic DNA from WI-38T
HP-1/2 in the BPTF gene
revealed a 1.5 fold increase in BPTF genomic dosage compared to WI-38T cells. Two sets of primers were used to detect the gene dosage of BPTF. One
set annealing to the 5-prime end of the BPTF gene (BPTF-exon 2) and the second set annealing to the 3-prime end of it (BPTF-exon 30).
doi:10.1371/journal.pone.0009657.g004
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human cancers, a clear gain of its locus was noticed.
As mentioned above, many types of human cancer demonstrate
rearrangements of the 17q region. Partial gain of chromosome
arm 17q is the most abundant genetic alteration in neuroblastoma
and constitutes the strongest genetic factor for adverse prognosis
[12]. It is assumed that one or more genes on 17q contribute to
neuroblastoma by a gene dosage effect. Furthermore, studies
aimed at mapping 17q breakpoints in neuroblastoma and assessing
their significance concluded that genes mapping between 17q21
and 17qter are important for neuroblastoma pathogenesis
[13,19,20,21]. Given that neuroblastoma is an embryonic tumor
it is tempting to speculate that the translocation revealed in WI-38
cells, which are derived from an embryonic origin, is analogous to
translocations occurring in neuroblastoma cases.
Attempts made at identifying the gene or genes in the 17q region
responsible for neuroblastoma promotion were unfruitful. The human
Bromodomain PHD finger Transcription Factor gene (BPTF) shown
here to be translocated resides within this breakable region.This gene is
transcribed into two different messengers and proteins: the 2,781
amino acid long BPTF protein [22] and the shorter fetal ALZ50-
reactive clone 1 (FAC1) which consists of only 801 N-terminal amino
Figure 5. The breakpoint region is highly enriched with repetitive elements. Twelve repetitive elements in the ,4 Kb breakpoint region are
depicted. Short interspersed nuclear elements (SINEs) are marked in dark grey and long interspersed nuclear elements (LINEs) are marked in light grey
(adopted from the UCSC genome browser).
doi:10.1371/journal.pone.0009657.g005
Figure 6. BPTF knock-down restricts proliferation. (A) Quantitative Real-Time PCR analysis on mRNA from WI-38T and WI-38T
HP-1/2 in the BPTF
gene revealed an increase in the endogenous BPTF mRNA in WI-38T
HP-1/2 cells. (B) Quantitative Real-Time PCR on mRNA from WI-38T and WI-
38T
HP-1/2 following BPTF knock-down. (si-BPTF-1 targeted the translocated region while si-BPTF-2 targeted the endogenous region of BPTF). (C)
Growth inhibition of cells by knocking-down BPTF is more efficient in WI-38T
HP-2 cells. Depicted is crystal violet staining of cells five days following si-
RNA transfection. (D) Quantification of the crystal violet from panel C, numbers above bars describe the fold change, depicted is a representative
from three independent experiments.
doi:10.1371/journal.pone.0009657.g006
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the BPTF sequence imply to transcriptional regulatory abilities such as
a DDT DNA binding domain [24], a PHD zinc finger, a glutamine-
rich acidic domain and a bromodomain [22]. Indeed, FAC1 was
suggested to regulate transcription by directly binding DNA [25] and
BPTF was shown to be involved in chromatin remodeling [26,27].
Cancer is a disease characterized by deregulation of transcriptional
programs and the majority of genes considered as oncogenes or tumor
suppressors are involved in the transcriptional aspect of tumorigenesis.
As transcription-regulators, several bromodomain-containing proteins
have been associated with malignancy and translocation breakpoints
have been detected in some of the genes encoding these proteins:
HRX/ALL-1 [28,29], TIF1 [30] and RFG7 [31]. These findings,
combined with our observations that the chromosomal region
harboring the BPTF gene is translocated and that this translocation
strongly correlates with a pre-malignant phenotype implies for the
involvement of BPTF/FAC1 in regulating cellular proliferation.
The means by which the translocated BPTF affects proliferation
are yet to be elucidated, in line with reported cases of deregulated
genes and proteins due to chromosomal aberrations, several
scenarios can be proposed. The translocation event may cause
BPTF to be translated as a truncated protein. Alternatively, the
protein function of BPTF/FAC1 may remain unchanged but its
transcriptional regulation is modified due to its new location in the
genome. A scenario of a fusion protein seems less plausible since
no aberrations were detected on chrX. However, deregulation of
endogenous BPTF due to a truncated protein is conceivable since
an up-regulation of endogenous BPTF was observed in cells
harboring the translocation. Such regulation could be mediated
for example by squelching of a BPTF transcriptional repressor (as
in dominant negative mechanisms) by the miscoded BPTF.
A case where a deregulated BPTF/FAC1 can affect proliferation
can be conceived: the physical interaction between FAC1 and the
Myc-associated zinc finger protein (ZF87/MAZ) reduces ZF87/MAZ
activity [32]. Interestingly, ZF87/MAZ is a negative regulator of the c-
myc proto-oncogene [33]. Therefore, an indirect positive regulation of
c-myc by FAC1 is feasible where FAC1 inhibits repressional
regulation of the c-myc promoter by ZF87/MAZ. This possible
regulation of BPTF/FAC1 over c-myc comes in accordance with the
observation that WI-38T
HP1 exhibit high c-myc levels [14] and the
Figure 7. The der(X)t(X;17) translocation is selected in tumors-derived from WI-38T
HP-1 cells harboring the GSE56 and H-Ras
V12
constructs. (A) The WI-38T
HP-1 cells that express the GSE56 and oncogenic H-Ras
V12 exhibit genomic instability. Spectral karyotyping (SKY) analysis
of WI-38T
HP-1 cells which were introduced with GSE56 and oncogenic H-Ras
V12 reveals genomic instability manifested by polysomy and several
genomic aberrations. (B) A SKY analysis of WI-38T
HP-1 tumor-derived cells is shown, the der(X)t(X;17) translocation is circled. (C) A FISH analysis on WI-
38T
HP-1 tumor-derived cells that harbor a shRNA against p53 (shp53) and oncogenic H-Ras
V12. The probe detecting chr17q24.3 (RP11-387O17 - red) is
visible on two copies of chr17 and on one copy of chrX. A probe detecting the most telomeric X chromosomal region (RP11-26A4) is marked in green.
doi:10.1371/journal.pone.0009657.g007
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proliferative phenotype as knock-down of BPTF restricts proliferation.
A situation in which a pro-growth gene (as BPTF seems to be) is
aberrantly expressed due to structural rearrangements of the
genome grants the cell harboring this aberrancy with a growth
advantage that allows it to overcome the natural obstacles
preventing transformation. After showing the connection between
the aforementioned translocation and a growth advantage
provided to the cells, and mapping the translocation breakpoint
to BPTF, we suggest that BPTF could play a cancer-promoting
role in neoplasms harboring chromosomal aberrations in 17q.
Materials and Methods
Cell culture and transfections
The immortalized primary human embryonic lung fibroblasts
(WI-38T and WI-38T
HP-1/2) were established and maintained as
described [14]. Knock-down of BPTF was conducted by transfection
with specific oligo-nucleotides using DharmaFECT3 reagent (both
from DHARMACON, Lafayette, CO). In the experiments described
in Figures 6B and 6C cells were plated in 6 cm plates 24610
4 in 6B
or 1610
4 in 6C and were transfected 48 h later with small interfering
RNA targeting BPTF or LacZ as a control. In Figure 6C cells were
stained with crystal violet five days post transfection.
Quantification of cell growth and colony formation assay
For the quantification of cells depicted in Figure 1A cells were
plated in 24-well plates (2610
5 cells per well) and were counted
every 24 h using Countess
TM automated cell counter (Invitrogen).
For the colony formation assay depicted in Figure 1B cells were
plated in 6-well plates (1610
2 cells per plate) and stained with
crystal violet 14 days later.
DNA and RNA isolation and Quantitative Real Time-PCR
(QRT-PCR)
For DNA extraction, cell pellet was resuspended in 400 ml
Buffer A (100 mM Tris-HCl, pH 7.5, 100 mM EDTA, 100 mM
NaCl, 0.5% SDS) and incubated at 65u for 30 minutes. 800 ml
LiCl/KAc solution was added followed by incubation on ice for 10
minutes. Next, lysate was centrifuged for 15 minutes at RT. 1 ml
of supernatant was transferred and 600 ml isopropanol was added,
Figure 8. Gain of the BPTF genomic locus and mRNA levels in human tumors. (A) Representative pictures of the various chromosomal
rearrangements in the BPTF locus in six human tumor types. FISH analysis using probe RP11-387O17 (detecting 17q24.3 region in the BPTF locus) and
a probe detecting chr17 centromeric material to distinguish between polysomy and gain of the BPTF locus. The nuclei presented are of lung
adenocarcinoma cells and are representative of the different probe patterns detected in the other tumors (colon, neuroblastomas and leukimias). a)
normal ploidy. b) chr17 polysomy. c) partial trisomy of 17q24.3. d) gain of 17q24.3. (B) A graph depicts the percentage of samples containing gain of
17q24.3 (a sample in which over 30% of cells exhibit gain was considered a positive sample) as assessed by FISH of a paraffin tissue array containing
143 tumor samples. (C) Expression of BPTF in several human tumors. Depicted is the relative expression of BPTF in several human cancers compared
to normal tissues as obtained from the ONCOMINE database.
doi:10.1371/journal.pone.0009657.g008
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with 70% ethanol and resuspended in 50 ml TE.
Total RNA was isolated using NucleoSpin kit (Macherey-Nagel)
according to the manufacturer’s protocol. A 2 mg aliquot of the
total RNA was reverse transcribed using Bio-RT (9597, BIO LAB)
and random hexamer primers. QRT-PCR was done with ABI
7300 instrument (Applied Biosystems, Foster City, CA) using
Platinum SYBR Green qPCR SuperMix (Invitrogen,Carlsbad,
CA). Two sets of primers were used to measure the genomic
dosage of BPTF. The first set annealing to the 5-prime end of the
BPTF gene (BPTF-exon 2- sense-GTG CTG CGG GTG TAC
TGT GA, anti-sense- AGG AAG AAC GTG ATG GTA CTC
CTT). The second set annealing to the 3-prime end of BPTF
(BPTF-exon 30- sense-CAC TAA GCT GTC AGC TCT GCT
CTT, anti-sense- TCG GCT CTG AGC TGC TCTT T). Two
sets of primers were used to measure the mRNA dosage of BPTF.
The first set annealing to the 5-prime end of the BPTF gene
(BPTF-exon 1-2- sense- CAG CAG CAC TCC AGG TAG GC
anti-sense-GGA GAA CGA GGC CGA TGT ACT). The second
set annealing to the 3-prime end of BPTF (BPTF-exon 30- sense-
CAC TAA GCT GTC AGC TCT GCT CTT, anti-sense- TCG
GCT C TGA GCT GCT CTT T). cDNA levels were normalized
to GAPDH (sense-ACC CAC TCC TCC ACC TTT GA, anti-
sense- CTG TTG CTG TAG CCA AAT TCG T).
Tissue arrays and anaphase fluorescence in situ
hybridization (FISH) analyses
ThetissuearrayswerepurchasedfromBiomax(www.biomax.us),
cat# - MC803 and MC2081. These arrays are IRB and HIPPA
approved. The paraffin sections contained 143 tumor samples from
six human cancer types (neuroblastomas, lung adenocarcinomas,
nephroblastomas, leukemias, colon cancer and retinoblastomas).
FISH was performed using combination of probes RP11-387O17
detecting 17q24.3 region in the BPTF locus labeled with green
fluochrome and a probe detecting chr17 centromeric probes -
labeled with red flurochrome (for labeling see metaphase FISH).
The slides were first deparaffinized with xylene and then incubated
in 0.1 mM citric acid pH 6 twice for 5 min in a microwave.
Following digestion with 4 mg/ml pepsin (Sigma P-7012) for
15 min at 37Cu, the slides were rinsed in 2XSSC for 5 min at room
temperatureandairdried.10 mlprobeswere addedtotheslidesand
covered with a coverslip and sealed with rubber cement. Slides were
co-denatured in an Omnislide in situ hybridization system (Hybaid
limited) at 80Cu for 5 min and then hybridized at 37Cu for 16 hrs.
The slides were washed according to probe specification and
counter stained with DAPI (49–69-diamidine-2-phenylindole). The
samples were viewedwitha Provis-Olympus fluorescent microscope
equipped with a 100W mercury lamp and DAPI, orange, green,
dual orange/green filters. Images were captured using the QUIPS
XL Genetics Workstation (Vysis). FISH samples were evaluated by
two microscopists. At least 100 nuclei were examined for each case.
Metaphase fluorescence in situ hybridization (FISH)
analyses
Metaphase spread was prepared from the cell lines using
standard techniques. The probes were labeled by nick translation
using a Nick Translation Reagent Kit with Spectrum Orange or
Spectrum Green according to the instruction provided by the
supplier (Abbot Molecular Inc.). The probes were ethanol
precipitated and resuspended each at 10 ml of hybridization
solution (50% Formamide, 2XSSC and 10% Dextran Sulfate).
Slides were denatured in 70% Foromamide /2XSSC at 72Cu, the
probes were denatured separately at 75Cu for 7 minutes and
applied to the slides for hybridization at 37Cu over night. After
washing at 72Cu in 0.4XSSC for 2 minutes, the slides were stained
with 4,6-diamidino-2 phenylindole (DAPI) in antifade medium.
Spectral karyotyping (SKY) analysis
Chromosome specific libraries generated by PCR from flow-
sorted human chromosomes were labeled with one of five different
nucleotides conjugated to five different dyes (FITC, Rodamine,
Texas Red, Cy5 and Cy5.5) or a combination thereof. All 24
chromosomes libraries were hybridized simultaneously to the
metaphases. After washing the slides were stained with 4,6-
diamidino-2 phenylindole (DAPI) in antifade medium. From each
case between 5-10 metaphases were captured using a fluorescent
microscope (Olympus BX51) using a custom designed triple band
pass filter (SKY, Chroma Technology, Battleboro, VT) that allows
simultaneous excitation of all dyes and measurement of their
emission spectra. The discrimination between the different spectra
was done using the SD300 spectral bio-imaging system. The
system enables the measurement of the full visible light spectrum
at each pixel of the image by using a Sagnac interferometer. A
classification algorithm was used to differentiate between different
spectra in the image and to assign pseudocolors to all the pixels
which have similar spectral characteristics. The DAPI image was
captured separately and inverted to give a G-banding like pattern.
The chromosomes were then sorted automatically into a karotype
table.
Comparative genomic hybridization (CGH)
DNA samples from primary WI-38 and WI-38T
HP-1 were
labeled and hybridized to Agilent custom CGH arrays covering
the 0.5-Mb region (the distance between probe RP11-387O17 and
RP11-304I14) on chromosome 17 with an average probe spacing
of 0.5 kb (www.agilent.com) using Agilent standard CGH
protocols [34]. A custom made oligonucleotide array designed
for CGH contained 12099 chrX and 9225 chr17 60-mer probes.
These probes included both coding and noncoding sequences on
these chromosomes. Probes design, for 60-mer probes, was
performed using the methods described in [35]. Design takes into
account uniqueness in the genome, thermodynamic uniformity
and seeks to maximize uniformity of coverage under these
constraints. The array design is uploaded for manufacturing using
Agilent’s eArray software.
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